## Clinical Context This patient presents with a classic obstructive pattern on spirometry (FEV₁/FVC <0.70) with moderate airflow obstruction (FEV₁ 50–69% predicted). The scooped-out expiratory flow-volume loop and preserved DLCO are hallmarks of COPD, not asthma or restrictive disease. ## Spirometry Pattern Analysis | Parameter | Value | Interpretation | |-----------|-------|----------------| | FEV₁/FVC | 0.68 | Obstructive (normal >0.70) | | FEV₁ | 58% predicted | GOLD Stage 2 (moderate) | | DLCO | Normal | Rules out emphysema-predominant disease | | Flow-volume loop | Scooped expiratory | Characteristic of COPD | **Key Point:** The post-bronchodilator FEV₁/FVC ratio <0.70 confirms fixed airflow obstruction consistent with COPD diagnosis, not asthma (which would show reversibility). ## Next Step Rationale **High-Yield:** Once COPD is diagnosed by spirometry, the immediate management priority is pharmacotherapy initiation based on GOLD guidelines, not further diagnostic testing. A long-acting beta-2 agonist (LABA) ± inhaled corticosteroid (ICS) is appropriate for GOLD Stage 2 disease. **Clinical Pearl:** Follow-up spirometry at 3 months assesses: - Response to therapy - Baseline for future decline monitoring - Need for therapy escalation ## Why Not the Other Options? 1. **High-resolution CT**: Indicated only if clinical suspicion for bronchiectasis, interstitial lung disease, or malignancy exists. This patient has a clear COPD diagnosis; imaging is not the next step. 2. **Bronchoscopy**: Reserved for hemoptysis, suspected malignancy, or recurrent infections—not for uncomplicated COPD diagnosis. 3. **Methacholine challenge**: Contraindicated in COPD (risk of severe bronchospasm) and unnecessary when diagnosis is already established by spirometry. **Mnemonic: COPD Management Sequence** — **D**iagnose (spirometry) → **I**nitiate therapy → **M**onitor response → **E**scalate if needed
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.